Latest Ratios: P/E Ratio -10.6x · EV/EBITDA 4.6x · ROE N/A. (1996–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $26M | $35M | $71M | $45M | $37M | $104M | $61M | $64M | $55M | $62M | $34M |
| Enterprise Value | $28M | $38M | $84M | $55M | $47M | $98M | $57M | $66M | $62M | $63M | $41M |
| P/E Ratio → | -10.57 | — | 173.40 | — | 13.24 | 49.52 | 16.67 | 27.96 | — | 26.87 | — |
| P/S Ratio | 0.81 | 1.10 | 2.23 | 1.42 | 1.22 | 3.58 | 1.96 | 2.00 | 1.87 | 2.43 | 1.49 |
| P/B Ratio | — | — | — | — | — | 24.74 | — | — | — | — | — |
| P/FCF | 4.87 | 6.61 | 29.58 | 34.84 | — | 106.18 | 7.62 | 11.22 | 11.66 | 10.98 | 7.42 |
| P/OCF | 4.66 | 6.33 | 11.85 | 5.00 | 4.32 | 13.06 | 7.21 | 10.04 | 10.24 | 10.79 | 6.91 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.19 | 2.61 | 1.76 | 1.55 | 3.40 | 1.83 | 2.07 | 2.11 | 2.47 | 1.76 |
| EV / EBITDA | 4.58 | 6.05 | 21.08 | — | 8.05 | 18.35 | 6.86 | 12.07 | 11.17 | 11.97 | 56.65 |
| EV / EBIT | 5.87 | — | 88.96 | — | 9.71 | 24.58 | 8.65 | 12.94 | 11.91 | 12.73 | — |
| EV / FCF | — | 7.16 | 34.72 | 43.03 | — | 100.60 | 7.10 | 11.65 | 13.13 | 11.16 | 8.78 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 76.6% | 76.6% | 75.2% | 73.1% | 71.0% | 68.9% | 69.0% | 68.5% | 70.8% | 73.5% | 75.0% |
| Operating Margin | 15.3% | 15.3% | 10.9% | -39.3% | 13.3% | 13.9% | 24.6% | 15.9% | 17.8% | 19.7% | 1.9% |
| Net Profit Margin | -7.7% | -7.7% | 1.3% | -30.4% | 9.1% | 7.2% | 11.6% | 7.2% | -2.9% | 9.1% | -5.7% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | 208.4% | 274.3% | — | — | — | — | — |
| ROA | -3.8% | -3.8% | 0.6% | -15.1% | 4.4% | 3.9% | 8.1% | 5.4% | -2.6% | 10.7% | -6.8% |
| ROIC | — | — | — | -235.3% | 84.7% | — | — | — | — | — | — |
| ROCE | 11.4% | 11.4% | 8.3% | -28.7% | 9.5% | 11.6% | 26.8% | 18.6% | 28.1% | 61.1% | 5.6% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | 0.67 | — | — | — | — | — |
| Debt / EBITDA | 0.52 | 0.52 | 3.26 | — | 1.99 | 0.53 | 0.75 | 1.64 | 2.35 | 1.39 | 13.63 |
| Net Debt / Equity | — | — | — | — | — | -1.30 | — | — | — | — | — |
| Net Debt / EBITDA | 0.46 | 0.46 | 3.12 | — | 1.70 | -1.02 | -0.50 | 0.44 | 1.25 | 0.19 | 8.77 |
| Debt / FCF | — | 0.55 | 5.14 | 8.19 | — | -5.58 | -0.51 | 0.43 | 1.47 | 0.18 | 1.36 |
| Interest Coverage | -0.13 | -0.13 | 0.50 | -9.81 | 3.18 | 2.89 | 4.26 | 2.99 | 3.34 | 3.78 | -1.62 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.59 | 0.59 | 0.58 | 0.45 | 0.49 | 0.75 | 1.13 | 1.00 | 1.91 | 0.91 | 0.69 |
| Quick Ratio | 0.57 | 0.57 | 0.55 | 0.42 | 0.45 | 0.71 | 1.07 | 0.93 | 0.87 | 0.89 | 0.66 |
| Cash Ratio | 0.17 | 0.17 | 0.16 | 0.05 | 0.09 | 0.40 | 0.64 | 0.48 | 0.45 | 0.48 | 0.31 |
| Asset Turnover | — | 0.51 | 0.49 | 0.51 | 0.47 | 0.48 | 0.67 | 0.74 | 0.69 | 1.06 | 1.18 |
| Inventory Turnover | 18.04 | 18.04 | 12.08 | 10.98 | 10.33 | 9.76 | 10.41 | 9.25 | 0.53 | 21.38 | 15.99 |
| Days Sales Outstanding | — | 79.16 | 83.41 | 76.58 | 72.72 | 66.38 | 74.09 | 69.95 | 73.30 | 73.70 | 63.96 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 12.6% | 9.3% | 2.8% | — | 20.7% | — | — | — | — | — | — |
| Payout Ratio | — | — | 502.5% | — | 276.9% | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | 0.6% | — | 7.6% | 2.0% | 6.0% | 3.6% | — | 3.7% | — |
| FCF Yield | 20.6% | 15.1% | 3.4% | 2.9% | — | 0.9% | 13.1% | 8.9% | 8.6% | 9.1% | 13.5% |
| Buyback Yield | 0.7% | 0.5% | 2.0% | 1.8% | 4.9% | 0.2% | 0.0% | 1.6% | 0.0% | 0.7% | 31.3% |
| Total Shareholder Yield | 13.3% | 9.8% | 4.8% | 1.8% | 25.6% | 0.2% | 0.0% | 1.6% | 0.0% | 0.7% | 31.3% |
| Shares Outstanding | — | $8M | $8M | $8M | $8M | $8M | $8M | $8M | $7M | $8M | $8M |
Critical liquidity and insolvency
According to recent market data, CCEL trades at a P/S multiple of 0.81 and a P/FCF of 4.87, suggesting that investors are pricing the firm as a declining storage utility rather than a high-growth clinical-stage biotech, despite the potential optionality embedded in its Duke University licensing agreement.
The negative P/E ratio of -10.57 underscores the company's inability to generate consistent bottom-line earnings, rendering traditional earnings-based valuation metrics largely irrelevant. The market's heavy discounting of the stock appears to reflect deep skepticism regarding the company's ability to convert its clinical pipeline into meaningful, non-dilutive cash flow.
As reported in financial statements, CCEL maintains a robust gross margin of 76.63%, yet this high-level efficiency is consistently eroded by elevated operating expenses, resulting in a net margin of -7.70% that highlights the company's struggle to achieve sustainable profitability despite its specialized service model.
The wide gap between gross and net margins suggests that the company's cost structure is heavily burdened by customer acquisition costs and administrative overhead. Investors should monitor whether these expenses are temporary investments in clinical development or structural inefficiencies that will continue to suppress earning power.
Based on reported figures, CCEL's return on invested capital has exhibited extreme volatility, swinging from 60.0% in 2024Q2 to -16.2% in 2024Q4, which indicates that the company is failing to consistently compound shareholder capital due to erratic operational performance and a lack of sustained margin expansion.
The inability to maintain a positive and stable ROIC suggests that the company's capital allocation strategy is currently value-destructive. The recent pivot toward clinical-stage investments appears to be consuming capital at a rate that the core storage business cannot support, warranting further investigation into the efficacy of these expenditures.
According to quarterly filings, CCEL's cash conversion cycle has fluctuated significantly, ranging from -67 days to 26 days, which suggests that the company lacks a predictable mechanism for managing its working capital and converting its service-based revenue into immediate, usable cash for operations.
The high variability in the cash conversion cycle, particularly the swings in days payable outstanding, implies that the company may be managing its liquidity by delaying payments to suppliers. This reliance on working capital management to bridge cash gaps is a precarious strategy that leaves the firm vulnerable to operational disruptions.
The most commonly misapplied metric for CCEL is the P/S ratio, which obscures the company's true financial health by failing to account for the massive deferred revenue liabilities that represent long-term service obligations rather than immediate cash-generating assets available to fund current clinical-stage research and development.
Analysts should instead focus on the change in deferred revenue and free cash flow to gauge the company's actual liquidity position. Relying on revenue multiples ignores the reality that a significant portion of CCEL's top-line is already committed to future service delivery, leaving little room for error in current cash management.
Includes 30+ ratios · 30 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CCEL stock.
Cryo-Cell International, Inc.'s current P/E ratio is -10.6x. The historical average is 40.1x.
Cryo-Cell International, Inc.'s current EV/EBITDA is 4.6x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 18.4x.
Based on historical data, Cryo-Cell International, Inc. is trading at a P/E of -10.6x. Compare with industry peers and growth rates for a complete picture.
Cryo-Cell International, Inc.'s current dividend yield is 12.63%.
Cryo-Cell International, Inc. has 76.6% gross margin and 15.3% operating margin. Operating margin between 10-20% is typical for established companies.
Cryo-Cell International, Inc.'s Debt/EBITDA ratio is 0.5x, indicating low leverage. A ratio below 2x is generally considered financially healthy.